u/Efficient_Ad5893

Magnite is the largest independent sell-side ad platform for connected TV. When Netflix, Disney, Vizio, or LG run ads on their streaming apps, there's a real chance Magnite is the infrastructure running the auction that decides which ad shows and what it sells for. Streaming now makes up the majority of US TV viewing time, and Magnite sits right in the middle of monetizing that shift.

The Q1 numbers showed real progress. CTV crossed 51% of the company's core revenue metric for the first time, up from 43% a year earlier, growing 30% year over year. Net income came in at $4.4 million, a sharp reversal from a $9.6 million loss in the same quarter last year. They also paid off $250 million in convertible debt, cutting net leverage to 0.7x, and management said they intend to be more aggressive with buybacks now that the balance sheet is cleaner.

Here's the part that makes this more than a normal earnings story. Google is in the middle of an antitrust case over its dominance in ad tech, and Magnite explicitly said in its own filings that a favorable ruling could meaningfully shift market share toward independent platforms like itself. On the earnings call, management said their win rate against Google in ad auctions is currently very low simply because of how Google's ecosystem is structured, and any behavioral remedy could produce close to instant gains. None of that upside is baked into current guidance, so if it happens, it's additive rather than already priced in.

The honest risk is real turnover. Four C-suite executives left within ten days of each other, including the CFO who announced his retirement. That's the kind of thing that makes investors nervous regardless of what the underlying numbers show, and it's a fair reason for some caution here.

Magnite trades around $13.60 with analyst targets averaging over $22, implying real upside even before factoring in any Google remedy. Anyone tracking the adtech space or this Google case specifically?

When you drill an oil or gas well, a huge amount of water comes up with the hydrocarbons. It's called produced water and it's salty, contaminated, and has to go somewhere. For every barrel of oil, a shale well can produce several barrels of this water. Select Water Solutions handles it. They gather it through pipelines, recycle it, and dispose of what can't be reused.

What makes the business interesting is the shift it's going through. The old model was spot service work, trucks and crews hired job by job, which is volatile and low margin. The new model is long-term contracted pipeline infrastructure. Producers dedicate acreage to Select for years, and Select builds permanent pipelines and recycling facilities to serve it. That turns lumpy oilfield service revenue into something closer to a utility.

The numbers show it working. Q1 2026 revenue was $366 million, but the standout was the Water Infrastructure segment hitting a record $96.7 million in revenue at a 56% gross margin. That's a remarkable margin for anything connected to oilfield services. They manage around 24 billion barrels of produced water a year, and management raised infrastructure growth guidance to 25 to 30% for 2026. There's also an early-stage lithium extraction angle, pulling lithium from the water they already handle, that could add royalty revenue from 2027.

Now the honest risks. Free cash flow was negative $67 million last quarter because they're spending heavily to build out the pipeline network. Infrastructure capex is guided to $200 to $250 million this year. They also did a stock offering that raised $191 million but diluted existing shareholders. You're funding a buildout, and the payoff depends on those contracted assets generating returns for years.

The way I look at Select is that it's an infrastructure company wearing an oilfield services costume. If the contracted utility-like model keeps growing, the market may eventually rate it like infrastructure instead of a cyclical driller. The capex and dilution are the price of getting there. Anyone here own the water midstream names?

Cal-Maine is the largest egg producer in the US. They sell the white and brown cartons you see everywhere, plus the higher-margin specialty stuff like cage-free and organic. No debt on the sheet, return on invested capital around 50%, and a dividend policy that pays out a third of net income every quarter. On the surface it looks like a deep value dream at a P/E around 5.

Here's the trap, and it's the whole point of this post.

That 5x earnings number is a cyclical illusion. Cal-Maine's profits are driven almost entirely by the wholesale price of eggs, and egg prices have been on a historic run because avian flu wiped out a huge chunk of the national flock and constrained supply. EPS went from 4 cents five years ago to nearly $25 at the peak. When you put a low multiple on peak-cycle earnings, the stock looks cheap right up until earnings normalize.

And they're normalizing now. Last quarter net sales fell 19% and EPS dropped 52% as egg prices came down from the highs. If you assume mid-cycle earnings are somewhere around $3 to $4 per share rather than $25, the valuation suddenly doesn't look cheap at all. This is the classic commodity stock mistake: cheapest on a P/E basis exactly when you should be most cautious.

What I find genuinely interesting about Cal-Maine is the diversification effort. They're pushing into prepared foods and specialty eggs to smooth out the cyclicality, targeting over 50% specialty mix over time. If that works, the earnings get less violent and the business deserves a higher multiple. If it doesn't, this stays a bet on the next bird flu outbreak driving egg prices back up.

So it's a value trap and a real business at the same time. The question is whether you're buying normalized earnings power or just peak-cycle profits dressed up as a bargain. How do people here handle commodity cyclicals where the P/E lies to you?

Cal-Maine is the largest egg producer in the US. They sell the white and brown cartons you see everywhere, plus the higher-margin specialty stuff like cage-free and organic. No debt on the sheet, return on invested capital around 50%, and a dividend policy that pays out a third of net income every quarter. On the surface it looks like a deep value dream at a P/E around 5.

Here's the trap, and it's the whole point of this post.

That 5x earnings number is a cyclical illusion. Cal-Maine's profits are driven almost entirely by the wholesale price of eggs, and egg prices have been on a historic run because avian flu wiped out a huge chunk of the national flock and constrained supply. EPS went from 4 cents five years ago to nearly $25 at the peak. When you put a low multiple on peak-cycle earnings, the stock looks cheap right up until earnings normalize.

And they're normalizing now. Last quarter net sales fell 19% and EPS dropped 52% as egg prices came down from the highs. If you assume mid-cycle earnings are somewhere around $3 to $4 per share rather than $25, the valuation suddenly doesn't look cheap at all. This is the classic commodity stock mistake: cheapest on a P/E basis exactly when you should be most cautious.

What I find genuinely interesting about Cal-Maine is the diversification effort. They're pushing into prepared foods and specialty eggs to smooth out the cyclicality, targeting over 50% specialty mix over time. If that works, the earnings get less violent and the business deserves a higher multiple. If it doesn't, this stays a bet on the next bird flu outbreak driving egg prices back up.

So it's a value trap and a real business at the same time. The question is whether you're buying normalized earnings power or just peak-cycle profits dressed up as a bargain. How do people here handle commodity cyclicals where the P/E lies to you?

Iren started life as a Bitcoin miner. That's the part that throws people off, because the company that exists today is barely related to that.

They build and operate AI data centers. They own the power, the buildings, and the GPUs, then rent that compute out to companies that need to run AI workloads. The whole model rests on one thing being scarce right now: large amounts of power-connected, GPU-filled data center capacity that can be brought online fast.

The deals are what make this interesting. In November 2025 they signed a five-year, $9.7 billion GPU cloud contract with Microsoft, including a 20% prepayment. Then in May 2026 they signed a separate $3.4 billion five-year deal with Nvidia to provide cloud capacity for Nvidia's own internal AI workloads. As part of that, Nvidia took a right to buy up to 30 million Iren shares at $70, which would be roughly a $2.1 billion stake. When Nvidia is willing to put equity into a customer, that's a real signal about how much they want the capacity.

They're targeting $3.7 billion in annualized run-rate revenue by the end of 2026 off a fleet scaling to 150,000 GPUs. The stock is up over 500% as all this came together.

Here's the honest risk and it's a big one. Iren isn't consistently profitable yet. The valuation already prices in flawless execution on an enormous buildout. They're taking on real capital intensity and debt to fund the data centers, and if they stumble on delivery timelines or the AI capex cycle cools, a stock that ran 500% can give a lot of it back quickly. There's also customer concentration, since Microsoft and Nvidia are a huge chunk of the contracted revenue.

So it's a genuine "the contracts are real but the execution risk is real too" situation. Anyone here own IREN or the other neocloud names? How are you thinking about the valuation after the run?

Molina runs Medicaid and Medicare plans for about 5 million people. States and the federal government pay them a fixed amount per member to manage care. When they keep medical costs below those payments, they keep the difference. It's a defensive business in theory because government health spending doesn't stop in a recession.

So why did the stock fall 28% in a single day earlier this year? That's the part worth understanding before anyone calls it cheap.

The problem is something called the medical care ratio, which is the percentage of premium dollars that goes out as medical claims. It jumped to 94.6% in Q4 from 90.2% a year earlier. When that ratio climbs, the margin Molina keeps gets crushed. Medical costs ran hotter than the rates they'd locked in, plus they took a $2 per share hit from retroactive Medicaid adjustments in California. Full year 2026 EPS guidance dropped to at least $5.00, down from $11.03 in 2025. That's not a small cut.

Here's the bull case. Management is openly calling 2026 a "trough year" for Medicaid margins. The logic is that rates reset higher to catch up with costs, a 5% Medicare Advantage rate increase is coming, and Medicaid rate restorations follow. If the trough thesis is right, earnings recover meaningfully from here and the current price looks like you bought at the bottom of the cycle.

The bear case is that this is a falling knife. Bank of America has an underperform rating citing low visibility into the risk pool. Medicaid membership is shrinking 6% this year. If medical costs keep outrunning rates, "trough year" becomes "first of several bad years."

So Molina isn't cheap for no reason. It's cheap because earnings fell off a cliff and the recovery depends on rates catching up to costs. The whole question is whether you believe the trough thesis. Anyone here have a view on the managed care cycle?

Huntington Ingalls is the only company in America that designs and builds nuclear-powered aircraft carriers. Not the leading one. The only one. They also build a large share of the Navy's submarines and amphibious ships out of two massive shipyards in Virginia and Mississippi.

Think about what that means as a business. The barriers to entry aren't high, they're basically infinite. You can't spin up a competitor to build nuclear aircraft carriers. The capital, the specialized labor, the security clearances, the decades of accumulated know-how, the government relationships. Nobody is replicating that. The closest thing to competition is General Dynamics on submarines, and even there the Navy needs both yards running at full capacity.

The backlog tells the story. It hit a record $54 billion last quarter, with some measures putting funded backlog closer to $57 billion. That's multiple years of revenue already locked in. Q1 revenue grew 13.4% to $3.1 billion and free cash flow swung to $730 million from a negative number a year ago. The geopolitical backdrop with naval expansion and submarine demand only adds to the order book.

The honest knock on Huntington Ingalls is margins. Shipbuilding is hard and they've been working through older fixed-price contracts signed before inflation spiked, which has pressured profitability. Labor shortages at the yards are a persistent challenge. This isn't a high-margin software business, it's a heavy industrial one with execution risk on every hull.

 

But for a company with a literal monopoly on a product the US government will keep buying for the next 30 years, the combination of a record backlog and improving cash flow is the kind of setup I want on a watchlist. Anyone here own the defense primes?

Insulet makes the Omnipod, a tubeless insulin pump that sticks to your skin, delivers insulin for three days, then gets thrown away and replaced. Diabetics who use it buy new pods continuously. It's a razor and blade model built around a chronic condition that doesn't go away.

The fundamentals look genuinely strong. Q1 revenue grew 34% year over year to $761.7 million. Net income nearly tripled. They've now posted ten straight years of 20% or more revenue growth. Management raised full year guidance. By most operational measures this is a company firing on all cylinders.

And yet the stock is down 41% year to date, sitting near its 52-week low. That's the part I keep turning over.

Part of it was the GLP-1 fear. When Ozempic and Mounjaro took off, the worry was that weight loss drugs would shrink the diabetes device market. The 2025 data didn't support that. If anything the bigger story is Insulet expanding into Type 2 diabetes, where Type 2 users now make up more than 40% of new US customer starts. The Type 2 population dwarfs Type 1, so that expansion roughly doubled their addressable market.

There was also a product recall on certain pods, which is a real concern for a device company, plus the broader selloff in anything trading at a premium multiple. Those explain some of the drop.

What I can't fully square is a business compounding revenue at 30%+ with an expanding market trading like something is breaking. Either the market sees a risk I'm underweighting, or Insulet is a case of price and fundamentals genuinely diverging. Curious which one people here think it is.

HP makes laptops and printers. That's the whole pitch and I understand why nobody gets excited about it. The stock is down around 24% over the past year while the S&P is up. It trades at roughly 9 times earnings and pays a dividend yielding close to 5%. The market has priced this thing for permanent stagnation.

But here's the part that made me look twice. Last quarter HP said about a third of every PC it shipped was an AI-capable machine with a dedicated neural processing chip. That's up sharply from the prior period. There's a Windows 10 end-of-support deadline pushing a corporate refresh cycle, and the AI PC upgrade wave is sitting right on top of it. A lot of enterprise machines are going to get replaced over the next couple of years whether anyone finds it exciting or not.

When a stock is priced like the business is dying and the underlying cycle quietly turns, the move higher doesn't need a blowout. It just needs the bear case to look slightly wrong. Lenovo already reported its fastest revenue growth in five years on the back of AI PCs, which is the same tailwind HP is exposed to.

The honest risk is that this has been a value trap before. PC demand is cyclical, printing is in slow secular decline, and memory costs are squeezing margins right now. People have been calling HP cheap for years while it kept drifting. Cheap can stay cheap for a long time.

The way I'm looking at HPQ is that you get paid almost 5% to wait while the AI PC cycle either re-rates it or it doesn't. That's a different risk profile than paying up for a high flier and hoping the growth holds.

Is this a real re-rating setup or just another year of value trap? Genuinely torn on it.

Every data center, every new power line, every onshored factory, every grid upgrade needs an enormous amount of steel. The AI infrastructure buildout that's driving all the chip enthusiasm has a physical layer underneath it, and that layer is mostly metal.

Steel Dynamics is one of the more efficient steel producers in the US. They run electric arc furnaces, which are cheaper and more flexible than the old blast furnace model, and they recycle scrap metal as a core part of the operation. The business has three legs: steel operations at about $13.9 billion in revenue, metals recycling at $4.4 billion, and steel fabrication at $1.4 billion. They've also been building out an aluminum segment.

The setup that interests me is the combination of the onshoring trend and the infrastructure demand hitting at the same time. Tariffs and reshoring policy push more manufacturing back to the US. AI and grid buildout push demand for the materials that go into construction. Both of those favor a domestic steel producer.

The stock trades around $282 and some cash flow models estimate fair value closer to $392. Earnings are forecast to grow north of 20% annually over the next few years, which is unusual for a company in a sector most people consider mature and cyclical.

That cyclicality is the honest risk with Steel Dynamics. Steel demand moves with the economy. A construction slowdown or a recession hits volumes and pricing at the same time. This isn't a set and forget holding, it's a position you size knowing the cycle can turn.

Anyone here playing the infrastructure side of the AI trade rather than the chips?

Most biotech at this market cap is pre-revenue, burning cash, and trading on hope. Harmony is the opposite. They have a drug on the market called WAKIX that treats narcolepsy. It did about $868 million in revenue in 2025 and management is guiding to over $1 billion in 2026. Q1 came in at $215 million, up 17% year over year. The company is profitable and self-funding, which for a biotech this size is genuinely rare.

So why does it trade this cheap? After spending some time on it, the answer is concentration risk and it's a real one.

Almost all the revenue comes from that single drug. WAKIX patent exclusivity runs to 2030. After that, generic competition can enter and the cash flow that supports the whole valuation comes under pressure. The entire bull case depends on what happens between now and then.

To their credit, management is clearly aware of it. They're filing for an extended release version of the drug to stretch the franchise into the 2040s. They have an orexin-2 agonist in early trials that could open a much larger market. There are several Phase 3 programs running in other CNS indications. They also just discontinued a Fragile X program after it failed a study, which is a reminder that not every pipeline bet works out.

So the cheap multiple isn't a free lunch. You're being paid to take on the risk that the pipeline either replaces the WAKIX concentration in time or it doesn't. Analyst fair value estimates sit meaningfully above the current price around $34, but those assume the patent holds and the pipeline delivers.

For anyone who follows Harmony or biotech generally, is the concentration risk enough to justify a P/E of 5, or is the market right to discount it this heavily?

The nuclear thesis has been well covered at this point. AI data centers need baseload power 24/7, nuclear is the only realistic answer at scale, Microsoft restarted Three Mile Island, Google and Meta are signing long-term nuclear agreements. Most people tracking this already know the setup.

What I find more interesting is how you actually position across the chain rather than just buying one miner and calling it done.

The miners:

Cameco is the obvious anchor. World's largest western uranium producer, Cigar Lake and McArthur River assets, up over 80% this year. If you want direct uranium exposure this is the cleanest way to get it.

Uranium Energy Corp is the US-based pure play. Just opened the first new US uranium mine in over a decade. Smaller, more volatile, more upside if the supply thesis plays out.

The royalty layer:

Uranium Royalty Corp collects royalties on uranium production without the operational risk of running a mine. Up 115% over the past year. Less explosive than the miners on the upside but the model is more defensive if production runs into issues.

The pick and shovel layer:

Vistra generates the actual power. Nuclear and gas assets with tech companies signing long-term contracts directly because they need baseload that never switches off. Benefits from nuclear demand without the uranium price risk.

Eaton makes the electrical infrastructure that goes into nuclear plants and data centers. 90 year old company, data center segment growing double digits, order book reflects the urgency hyperscalers are operating with.

These aren't all equivalent positions. The miners are the most leveraged to uranium spot price. The royalty is the most defensive. Vistra and Eaton are infrastructure plays that benefit from nuclear buildout without caring much about whether uranium is at $80 or $120 per pound.